ATS Stat

HomeATS Stat ▶ Stat August 21, 2019
Stat August 21, 2019

ATS 2020 Call for Abstracts

The ATS is now accepting submissions of scientific and case report abstracts on all aspects of respiratory disease, critical care, and sleep medicine. Abstracts can report on basic, translational, and clinical science research; epidemiologic, social, biobehavioral, and psychosocial investigations; or educational and quality improvement projects.

  • Scientific Abstracts: Research on respiratory disease, critical care and sleep medicine, including quality improvement projects.
  • Case ReportsInteresting and unique reports describing a single clinical case.


For information on submitting scientific abstracts and case reports, please contact the American Thoracic Society at Submit your abstract now!

Deadline: 5 p.m. EST, Oct. 30, 2019


Assemblies Issue Call for Nominations

As a member of the American Thoracic Society, we greatly value your input. Several ATS assemblies are seeking internal nominations for leadership positions.

Submission of a nomination does not guarantee selection by the Nominating Committee. All final candidates will be contacted by the Nominating Committee Chair or its members.
Deadline:  Aug. 31, 2019


Opportunities with PAR

The patient perspective is paramount to our work at the American Thoracic Society, and since 2001, the ATS Public Advisory Roundtable (PAR), along with PAR partners comprised of various patient advocacy groups, has opened the Society to patients and patient advocacy groups.
Thanks to our PAR partners, ATS members have access to many disease-specific resources for researchers and practitioners These resources include everything from free CME and research grant opportunities (including fellowships!) to patient-registries of potential study participants. The large number of patient-activists involved with these groups mean that these organizations are able to provide our members with opportunities to learn from focus groups, surveys, and research publications that focus on the patient voice.
Click here to see a sample of the PAR resources available to ATS researchers and practitioners and watch patients speak to the importance of research now!


Asthma/Allergy Patient Education Day

As part of "Asthma/Allergy Week at the ATS" and in conjunction with PAR partner the Allergy & Asthma Network, the American Thoracic Society will have an Onsite Patient Education Day in Chicago, IL at the Ann & Robert H. Lurie Children's Hospital.

When: 9 a.m. - 3:30 p.m. CT, Aug. 24, 2019
Where: Ann & Robert H. Lurie Children's Hospital, Chicago, IL, and online. Register now to join the webinar!


ATS Welcomes FDA Approval of Pretomanid in Global Fight Against TB

The U.S. Food and Drug Administration recently approved use of pretomanid in treating tuberculosis. It was developed by TB Alliance, a non-profit drug developer.

“While TB can be cured using antibiotics, many of these drugs were developed more than 50 years ago. Drug resistance is associated with poor patient outcomes. It is estimated that as many as 20 percent of TB cases are caused by a strain that is resistant to one of the first or second line of TB drugs, and 5 percent are resistant to both INH and Rifampin, a hallmark of multidrug-resistant TB (MDR),” said David Lewinsohn, MD, PhD, chair of the International Health Committee at the ATS and TB researcher. “Of even greater concern, roughly 10 percent of these are considered extremely drug­ resistant (XDR), with additional resistance to second-line drugs. The ATS welcomes the FDA's approval of pretomanid, TB Alliance's new treatment for XDR and some forms of MDR-TB. Availability of this novel treatment is a significant advancement in the fight against TB. The ATS congratulates TB Alliance and its partners.”

To learn more, visit TB Alliance.